02196 FOSUN PHARMA
- 13.580
- -0.240-1.74%
FOSUN PHARMA News
Here's Why Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) Has A Meaningful Debt Burden
Pharmaceutical stocks have become a transitional theme at present, and the performance line may be further valued by the market.
Track the entire lifecycle of the main sector.
Shanghai Fosun Pharmaceutical (Group) Subsidiary's Cancer Drug's NDA Accepted by NMPA
Shanghai Fosun Pharma's New Cancer Drug Application Accepted
FOSUN PHARMA (600196.SH): The registration application for the injectable Raltitrexed Pharmaceutical has been accepted.
FOSUN PHARMA (600196.SH) announced that its controlling subsidiary, Gismay (Wuhan) Pharmaceutical Co., Ltd. ...
On December 30, FOSUN PHARMA (02196.HK) spent 4.94 million Hong Kong dollars to repurchase 0.35 million shares.
Gelonghui reported on December 30 that FOSUN PHARMA (02196.HK) announced that on December 30, it spent 4.94 million Hong Kong dollars to repurchase 0.35 million shares.
How is the quality and supply of Pharmaceuticals guaranteed? The National Healthcare Security Administration held a symposium on centralized procurement of Pharmaceuticals.
On December 26, 2024, the National Healthcare Security Administration held a symposium on centralized procurement of Pharmaceuticals, inviting representatives from the National Medical Products Administration, selected Pharmaceutical enterprises, and research Institutions to communicate and exchange views on recent societal concerns regarding quality assurance of centrally procured Pharmaceuticals and innovative development in the Industry, and to listen to opinions and suggestions.
Guangxi Wuzhou Zhongheng Group (600252.SH): A subsidiary plans to participate in the establishment of FOSUN PHARMA (Nanning) Co., Ltd.
Gelonghui reported on December 27 that Guangxi Wuzhou Zhongheng Group (600252.SH) announced that in order to meet the needs of the company's Business development, further expand the layout of the overseas market Business and enhance comprehensive competitiveness, Guangxi Wuzhou Zhongheng Group's wholly-owned subsidiary Zhongheng Yixin plans to establish a joint venture with the wholly-owned subsidiary of FOSUN PHARMA, Shanghai FOSUN PHARMA Industrial Development Co., Ltd. (referred to as "FOSUN Industrial Company"), and Nanning Industry Investment Unified Investment Group Co., Ltd. (referred to as "Unified Investment Group"). The registered capital of the joint venture is 100 million yuan, of which FOSUN Industrial Company contributes 5,100.
On December 27, FOSUN PHARMA (02196.HK) spent 2.8723 million Hong Kong dollars to repurchase 0.2045 million shares.
On December 27, Gelonghui reported that FOSUN PHARMA (02196.HK) announced the repurchase of 0.2045 million shares for HKD 2.8723 million on December 27, 2024, with a repurchase price of HKD 13.94-14.1 per share.
Shanghai Fosun Pharmaceutical Subsidiary Signs Cooperation, License Deal
The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."
In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.
FOSUN PHARMA (600196.SH) has signed a cooperation and licensing agreement with Palleon, intending to carry out joint clinical research on the licensed product Hanlikang.
FOSUN PHARMA (600196.SH) announced that its controlling subsidiary HENLIUS signed an agreement with Palleon...
FOSUN PHARMA (600196.SH): A subsidiary has signed a licensing agreement.
Gelonghui, December 19 - FOSUN PHARMA (600196.SH) announced that on December 19, 2024, its holding subsidiary HENLIUS signed a "Cooperation and License Agreement" with Palleon. According to the agreement, both parties will collaborate on the global development of Palleon’s investigational product E-602 and related combination therapy solutions within the field (i.e., for the treatment of human diseases) based on their respective patents and proprietary technologies, and will carry out commercialization in their respective licensed areas.
Shanghai Fosun Pharma Moves Hong Kong Office
Regent Pacific's Strategic Partners Submits NDA for Premature Ejaculation Drug in China
Market Cool On Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s (SHSE:600196) Earnings
Hong Kong stocks moved | HENLIUS (02696) opened more than 4% higher, FOSUN PHARMA stated that the prerequisites for the merger with HENLIUS have been met.
HENLIUS (02696) opened over 4% higher, and as of the time of reporting, it increased by 4.72%, trading at 23.3 Hong Kong dollars, with a transaction volume of 2.1972 million Hong Kong dollars.
Shanghai Fosun Pharmaceutical Moves Forward With Henlius Merger
Sinolink: The end of year centralized purchasing expectations are gradually being cleared, and the pharmaceutical sector行情 is expected to gradually start.
The pharmaceutical Sector is currently in a process of a triple reversal in performance, policies, and funding, with full confidence in the recovery of revenue profit growth and market resurgence of listed companies in the Sector by 2025.
Fosun Pharmaceutical Buys Back Nearly 3 Million Yuan Worth of Shares
No Data
